Case Report

Remission of Cognitive Deficits in Parkinson’s Disease: Recovery from a Nonamnestic Mild Cognitive Impairment or Psychiatric Symptoms Remission?

Jonas Jardim de Paula,1,2,3 Marco Túlio Gualberto Cintra,3 Débora Marques Miranda,2 Maria Aparecida Camargos Bicalho,4 Edgar Nunes Moares,3,4 and Leandro Fernandes Malloy-Diniz1,2,5

1 Laboratório de Investigações Neuropsicológicas (LIN), Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
2 INCT de Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Avenida Alfredo Balena 190, 30130-100 Belo Horizonte, MG, Brazil
3 Instituto Jenny de Andrade Faria de Atenção à Saúde do Idoso, Hospital das Clínicas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
4 Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
5 Departamento de Saúde Mental, Faculdade de Medicina, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil

Correspondence should be addressed to Jonas Jardim de Paula, jonasjardim@gmail.com

Received 30 July 2012; Accepted 1 October 2012

Academic Editors: J. S. Brar, F. Pillmann, and J. Saiz-Ruiz

Copyright © 2012 Jonas Jardim de Paula et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mild cognitive impairment is a clinical condition more frequent in patients with Parkinson’s disease than in general population. The nonamnestic presentations, usually characterized by executive dysfunction, are most prevalent. We present a case report of a Parkinson’s disease patient diagnosed with nonamnestic mild cognitive impairment that showed complete remission of cognitive symptoms after one year. We discuss the possible causes for the remission, focusing on the treatment of medical conditions such as a major depressive episode and vitamin B12 deficiency, in addition to the change of pharmacological treatment. In a third assessment, cognitive performance remained normal. The case report highlights the importance of controlling clinical comorbidities on the assessment and followup of mild cognitive impairment, especially on Parkinson’s disease.

1. Introduction

The concept of mild cognitive impairment (MCI) in Parkinson’s disease refers to a cognitive disorder where the subject shows an objective impairment in one or more cognitive domains and lack of or only mild functional impairment [1]. Due to the absence of uniformity in diagnostic criteria, there is little agreement in the literature on what subtype of MCI (amnestic × non-amnestic, single domain × multiple domain) is the most frequent in Parkinson’s disease.

The often used criteria for the diagnosis of MCI take into consideration the cognitive performance of the subject and establish that the patient should have a performance in terms of 1.5 standard deviations below the population mean of those subjects with the same age and years of formal education [2]. These same criteria are recommended considering MCI diagnosis in Parkinson’s disease [1]. Nonetheless, there is evidence that MCI is undiagnosed in Parkinson’s disease, and this fact can be related to the excessive use of screening tools, which are less sensitive to the cognitive decline observed in this population [3].

In Parkinson’s disease patients, MCI is more prevalent than in general population, affecting about 30% of the individuals, and the nonamnestic executive is the most
commonly diagnosed form [4, 5]. The conversion rate to
dementia is about 70% in four years [6]. There is little
evidence that MCI is reversible considering data from pop-
ulation and longitudinal studies [7]. Nonetheless, these data
are from studies in general population and in those subjects
with conversion to dementia syndromes. Mamikonyan and
colleagues [3] suggest that in Parkinson’s disease some causes
of cognitive impairment are reversible, such as daytime
sleepiness and psychiatric symptoms. In this report, we
present a case of nonamnestic MCI in Parkinson’s disease
and its remission of cognitive impairments after one year. We
thereafter discuss the possible mechanisms underlying this
remission.

2. Case Description and Clinical Exam

BS is a 53-year-old male, 8 years of formal education,
moved and retired from his former occupational activities,
and Parkinson’s disease diagnosed in 1999. In 2010, the
patient was referred by his neurologist to the Instituto
Jenny de Andrade Faria de Atenção à Saúde do Idoso, a
secondary public health unit of Belo Horizonte city, for
further evaluation. The initial hypothesis questioned by the
neurologist was dementia related to Parkinson’s disease.

According to the patient’s wife, since 2009 BS had been
showing repetitive behavior, psychomotor slowness and inat-
tention. No memory complaints, temporal or topographic
disorientation, and language or reasoning impairments were
related. The primary complaints initiated after the patient’s
retirement and beginning of sexual dysfunction. The physical
exam showed dyskinesia (of chorea type) on superior limbs
and chin. No impairment in basic or instrumental daily life
activities was related.

Neuropsychiatric symptoms on the first exam were
related. According to the neuropsychiatric inventory [8],
signs of delusional thoughts of infidelity (4), depression
(1), anxiety (8), euphoria (2), disinhibition (2), and irriti-
tability/lability (2) were identified. The most dysfunctional
symptom was the delusional thoughts, which were affecting
the patient’s relationship with his wife. The patient was
also diagnosed with a major depressive episode considering
the DSM-IV criteria. His serum levels of B12 vitamin were
low (114 pg/mL). The magnetic resonance imaging showed
signs of diffuse cortical atrophy. On the first assessment, the
patient was being treated with Amantadine (300 mg/day),
Levodopa/Benserazide (250 mg/day), and B12 vitamin (5000
units/2 times per month).

The patient was submitted to a cognitive screening
conducted by the gerontologist. The screening was composed
by the Brazilian versions of the Minimental State Exam [9],
the Pfeffer functionality index [10], the verbal learning of
the CERAD battery [11], the Category Fluency Test [11], and
the Clock Drawing Test [12]. Table 1 shows these preliminary
results.

The clinical impression was of a nonamnestic MCI
secondary to Parkinson’s disease, a major depressive episode,
B12 vitamin deficiency and erectile dysfunction. Because of
the clinical findings, the anticholinergic drugs (Amantadine
and Levodopa/Benserazide) were gradually discontinued,
and the Pramipexole was raised to 3 mg/day. A 25 mg/day
dose of Nortriptyline was initiated, gradually increased to
100 mg/day. The B12 vitamin reposition was maintained.
After the clinical exam, the patient was referred to neu-
ropsychological assessment for a better clarification of the
cognitive symptoms.

3. Neuropsychological Assessment

The patient was examined by a clinical neuropsychologist
using a comprehensive protocol several cognitive functions
but focusing on executive functioning. The rationale of
the neuropsychological assessment used was based on a
hierarchical cognitive architecture model [13], aiming at the
assessment of global cognitive functioning, memory, lan-
guage, processing speed, visuospatial abilities, and executive
functions. The following tests were used on the assessment.
Although the diagnosis was performed before the most
recent consensus [1], our guidelines for the MCI diagnosis
were very similar to the levels I and II assessment of
MCI: a more general impairment on a validated cognitive
scale for Parkinson’s disease dementia, impairment (at least
1.5 standard deviation below the age/education population
reference value) in at least two validated neuropsychological
tests for the specific cognitive domain and lack of functional
impairment in basic and instrumental daily life activities.

3.1. Cognitive Status and Global Measures. The Dementia
Rating Scale (DRS) [14] total score was chosen for global
cognitive screening, since this test was well suited for the
diagnosis of cognitive impairment in Parkinson’s disease
[15].

3.2. Episodic Memory. The Brazilian version of the Rey
Auditory Verbal Learning Test (RAVLT) [16], a complex
figure recall [17] and the DRS Memory subscale [14] were
used as episodic memory measures. The components A6
(immediate recall), A7 (delayed recall), Total (learning) and
recognition (recognition memory) from RAVLT, as well the
immediate and delayed recall of the complex figure, and the
total score of DRS Memory Subscale were selected as episodic
memory measures.

3.3. Language. The TN-LIN is a naming test adapted for
Brazilian elders [18] that uses stimuli more common to
our patients than the other more traditional naming tests

| Measure                      | Patient’s score | Cut-off |
|------------------------------|-----------------|---------|
| Minimental state exam        | 26              | 22      |
| Clock drawing test           | 4               | 3       |
| Category fluency (animals)   | 15              | 11      |
| Verbal learning (total words)| 20              | 13      |
| Verbal learning (recall)     | 6               | 4       |
| Verbal learning (recognition)| 10              | 7       |
| Pfeffer index                | 0               | 5       |

Table 1: Patient’s cognitive screening (January 2010).
do, and it was used for the assessment of language. The Brazilian version of the Token Test [19], a measure of verbal comprehension, was also selected for this assessment.

3.4. Processing Speed. We used a “Miniverbal” test for the assessment of this cognitive domain. The 5 Digits Test [20] is a stroop effect test designed to be culture free. It uses a numeric/counting stroop paradigm and assesses automatic attentional process (reading numbers and counting small figures), a simple measure of processing speed [21].

3.5. Visuospatial Abilities. The Clock Drawing Test [12] is commonly used for the assessment of constructional abilities, and was selected for the exam. The “Construction” subscale of the dementia rating scale [14], an adapted complex figure copy [17], and the Stick Design Test [22] were also selected as measures of this function.

3.6. Executive Functions. The assessment of this multifaceted cognitive domain was carried out focusing on its specific components. The “Initiative/Perseveration” subscale of the DRS was used as a more general measure of executive functioning. The Planning Skills were assessed by a modified version of the Tower of London Test which is more sensitive for mild cognitive impairment [23]. Fluency was measured by a verbal test, the Category Fluency of “Fruits” [24] and a drawing test, the Modified Five-Point Test [25]. On this last measure, the perseverations and strategy indexes were also evaluated. The 5 Digits Test [21] components of inhibition (time, errors, and executive score) were used as a measure of Inhibitory Control. For Categorization the subscale “Conceptualization” of the dementia rating scale was selected [14]. Finally, the perseverations of the Modified Five-Points Test and the components of shifting (time, errors, and executive score) of the 5 Digits Test [21] were used as a measure of Cognitive Shifting. These conjunct measures provide a comprehensive method for the assessment of executive functions.

Table 2 shows the assessment results. For better interpretation, all patient raw scores were transformed in Z scores based on the Brazilian normative values and corrected by age, formal education, and gender when necessary. Time, errors and perseverance scores were multiplied by −1 for easier analysis. Considering the threshold of 1.5 standard deviations below the normative reference values, the patient shows impaired performance on several executive functions measures, especially those related to fluency, inhibitory control, and cognitive shifting (Figure 1). The impairments in processing speed (about 1 SD below the reference value) could mediate the deficits in inhibitory control, cognitive shifting and fluency tasks; however, the impairment was present even in the nontimed scores, suggesting a loss of speed and efficiency. The data was then discussed by the multidisciplinary team, considering cognitive symptoms presented, its onset and progression, the neuropsychological profile presented, and the biases due to other clinical conditions besides PD which could underlie the cognitive impairment (depression, reduced vitamin B12, and patients pharmacological treatment). The diagnosis of MCI was proposed by the multidisciplinary team, and the patient went for followup.

The patient was reevaluated one year later. There were remission of depressive and psychotic symptoms, normalization of B12 vitamin levels, and good acceptance for the new pharmacological treatment. Cognitive complaints were milder. On this assessment, parallel forms of the neuropsychological tests, when available, were used. The results show
Table 2: Neuropsychological assessment.

|                          | First assessment (Jan/2010) | Second assessment (Jan/2011) | Third assessment (Jan/2012) | Reference value |
|--------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
|                          | Raw score | Z score | Raw score | Z score | Raw score | Z score | Mean | SD  |
| **Screening tests**      |           |         |           |         |           |         |      |     |
| MMSE                     | 26        | -1,1    | 29        | 0,4     | 29        | 0,4     | 28,3  | 2,0 |
| DRS                      | 121       | -1,9*   | 137       | 0,6     | 137       | 0,6     | 133,2 | 6,3 |
| **Memory**               |           |         |           |         |           |         |      |     |
| Memory (DRS)             | 25        | 1,3     | 25        | 1,3     | 25        | 1,3     | 22,4  | 2,0 |
| RAVLT (immediate recall) | 11        | 0,2     | 14        | 1,3     | 14        | 1,3     | 10,4  | 2,7 |
| RAVLT (delayed recall)   | 9         | -0,3    | 13        | 1,3     | 13        | 1,3     | 9,8   | 2,4 |
| RAVLT (recognition)      | 13        | 0,4     | 14        | 0,9     | 14        | 0,9     | 12,1  | 2,1 |
| Complex figure (immediate recall) | 48         | -0,8    | 59        | -0,1    | 65        | 0,3     | 60,0  | 16,0|
| Complex figure (delayed recall) | 47         | -0,6    | 75        | 1,4     | 70        | 1,1     | 55,0  | 14,0|
| **Language**             |           |         |           |         |           |         |      |     |
| Token test               | 30        | 0,0     | 35        | 1,3     | 33        | 0,8     | 30,0  | 4,0 |
| TN-LIN (naming)          | 64        | 0,7     | 64        | 0,7     | 62        | 0,3     | 60,2  | 5,7 |
| **Processing speed**     |           |         |           |         |           |         |      |     |
| 5 Digits test (reading)  | 30        | -1,2    | 27        | -0,6    | 23        | 0,3     | 24,3  | 4,9 |
| 5 Digits test (counting) | 33        | -1,4    | 28        | -0,2    | 26        | 0,3     | 27,3  | 4,2 |
| **Visual-spatial**       |           |         |           |         |           |         |      |     |
| Constructional praxis (DRS) | 6     | 0,3     | 6         | 0,3     | 6         | 0,3     | 5,8   | 0,8 |
| Stick design test        | 12        | 0,3     | 12        | 0,3     | 12        | 0,3     | 11,9  | 0,5 |
| Clock drawing            | 4         | -0,1    | 4         | -0,1    | 4         | -0,1    | 4,1   | 1,3 |
| Complex figure copy      | 63        | -1,8*   | 83        | -0,5    | 85        | -0,3    | 90,0  | 15,0|
| **Executive functions**  |           |         |           |         |           |         |      |     |
| Global measure           |           |         |           |         |           |         |      |     |
| Initiative/perseveration (DRS) | 30   | -1,1    | 37        | 0,8     | 36        | 0,5     | 34,1  | 3,7 |
| **Fluency**              |           |         |           |         |           |         |      |     |
| 5 Points test (unique drawings) | 19 | -1,6*   | 23        | -0,7    | 25        | -0,2    | 26,1  | 4,5 |
| 5 Points test (strategies) | 0  | -1,6*   | 4         | -0,6    | 4         | -0,6    | 6,22  | 3,84|
| Category fluency (fruits) | 12 | -1,5*   | 17        | 1,0     | 16        | 0,5     | 15,0  | 2,0 |
| **Categorization**       |           |         |           |         |           |         |      |     |
| Conceptualization (DRS)  | 26        | -2,6*   | 35        | -0,1    | 37        | 0,4     | 35,5  | 3,7 |
| **Planning**             |           |         |           |         |           |         |      |     |
| Tower of London          | 39        | 0,9     | 37        | 0,6     | 37        | 0,6     | 32,8  | 6,7 |
| **Inhibitory control**   |           |         |           |         |           |         |      |     |
| 5 Digits test (inhibition time) | 59  | -2,7*   | 41        | -0,7    | 39        | -0,5    | 34,6  | 9,0 |
| 5 Digits test (inhibition errors) | 7  | -3,3*   | 2         | 0,1     | 2         | 0,1     | 2,1   | 1,5 |
| 5 Digits test (executive inhibition) | 29 | -2,0*   | 14        | 0,2     | 13        | 0,4     | 15,4  | 6,8 |
| **Cognitive shifting**   |           |         |           |         |           |         |      |     |
| 5 Digits test (shifting time) | 78  | -2,8*   | 52        | -0,6    | 49        | -0,3    | 45,4  | 11,5|
| 5 Digits test (shifting errors) | 11 | -3,4*   | 3         | 0,7     | 4         | 0,2     | 4,3   | 2  |
a marked cognitive improvement in executive functions and remission of neuropsychiatric symptoms. Based on this data, we considered the remission of the nonamnestic MCI diagnosis. One year later, a new assessment confirmed the stability of cognitive performance. An FDG PET-CT exam performed one week after the last neuropsychological assessment reveals no significant change signs on cerebral cortex, cerebellum, basal ganglia, and thalamus glucose metabolism.

4. Discussion

Our findings indicated that after controlling for clinical aspects such as depression, B12 deficiency, and inadequate pharmacological treatment, the cognitive deficit which led to the diagnosis of nonamnestic MCI associated with Parkinson’s disease could be remitted. Those three clinical conditions are associated with cognitive impairment and might have contributed for the patient’s performance on cognitive tests.

Patients with Parkinson’s disease and without dementia usually present cognitive impairment [1, 26], even when more general cognitive measures such as the Miniminal State Exam suggests average results [3]. Since the cognitive performance of Parkinson’s disease patients follows a non-normal distribution [27], the use of strictly objective criteria (such as the 1.5 standard deviation in only one test) could lead to misguided results, demanding a more comprehensive diagnostic approach. Usually, the MCI diagnosis is performed after subjective complaint of cognitive changes. For our patient, only 10 years after the diagnosis of Parkinson’s disease, the subjective cognitive complaints were related, leading to the cognitive assessment. On the first assessment, the diagnosis was performed after the convergent finding of executive impairment on different neuropsychological tests, even with the normal Miniminal State result, lack of impairment on basic and instrumental daily life activities, no signs of dementia according to the standard diagnosis procedures.

Anticholinergic drugs as the tricyclic antidepressants, antipsychotics, antihistamines, and antiparkinsonians usually show a range of side effects in late life, such as falls, visual blurring, delirium, and more pronounced neuropsychiatric symptoms [28]. A prospective study [29] indicated that anticholinergic drugs may impair attentional processes but are not associated with progressive cognitive decline. In a transversal study, other authors [30] related a selective impairment on verbal episodic memory. Impaired verbal episodic memory is the most common cognitive impairment due to use of anticholinergic drugs, although there is no consensus about this pattern. The impairment is not sufficient to cause dementia, but it may be related to mild and reversible cognitive deficits. In our patient, the change from Amantadine and Levodopa/Benserazide to Nortriptyline and Pramipexole was associated with better cognitive performance on executive functions tests, even when we consider the anticholinergic effect of these new drugs [31].

The association between B12 vitamin and cognition still remains unclear. Although some studies associated this nutrient with cognition [32], others prove to be inconclusive [33]. A recent study [34] suggests that a specific marker of B12 deficiency (Methylmalonate) might affect cognitive performance, having brain volume atrophy, changes in white matter integrity, and cerebral infarcts as mediators. Blasko and colleagues [35] showed that B12 serum levels are not related to cognitive performance, but the supplementation of B12 associated with folic acid might reduce the conversion rate from MCI to dementia, probably by the reduction of homocysteines. These results, however, are controversial, since other studies [36] did not show convergent findings. It is not clear how B12 vitamin deficit in our patient might be associated with the observed cognitive impairment, but it is a hypothesis for the MCI remission.

It is important to note that the cognitive improvement presented by the patient could be associated with the remission of depressive symptoms due to pharmacological therapy. The role of depressive symptoms as moderators of cognitive performance is well established in neuropsychology [37, 38]. Although the underlying mechanism of how depression associates with cognitive impairment is not completely clear, the changes on mesial temporal structures such as the hippocampus and amygdala associated with the disruption of frontostritial connections may underlie the frequently related executive functions and episodic memory impairments in depression [38]. Recently, Sexton and colleagues [39] suggested that the executive dysfunction and the slowness of processing speed, two core features of cognitive impairment in depression, may mediate the deficits in other cognitive domains. In this regard, depression treatment may have promoted a better cognitive performance in our patient. A recent review on MCI in Parkinson’s disease [40] described the multiple pathogenic mechanisms for cognitive impairment, considering a degenerative, a vascular and

| Table 2: Continued. | First assessment (Jan/2010) | Second assessment (Jan/2011) | Third assessment (Jan/2012) | Reference value |
|--------------------|---------------------------|----------------------------|---------------------------|---------------|
|                    | Raw score | Z score | Raw score | Z score | Raw score | Z score | Mean | SD  |
| 5 Digits test (executive shifting) | 48     | −2,5*   | 25     | 0,1  | 26     | 0,0  | 26,1 | 8,7 |
| 5 Points test (% perseveration) | 19     | −2,8*   | 4      | 0,1  | 4      | 0,1  | 4,5  | 5,2 |

MMSE: minimental state exam, DRS: dementia rating scale, and * equal or below the 1.5 SD threshold.
a psychiatric component. Even in the presence of Parkinson’s disease, our patient also had a major depressive episode diagnosis, which, at least partially, may be related to cognitive impairment.

5. Conclusion

Our case report is an example of remission of a cognitive deficit in a nonamnestic MCI associated with Parkinson’s disease. Considering the multifactorial etiology of MCI, our results show the relevance of a comprehensive assessment and followup in these cases. Furthermore, our results highlight areas for future studies such as the followup of patients with MCI related to Parkinson’s disease after pharmacological interventions and the role of psychiatric disorders as moderators in cognitive deficits in this disorder.

Acknowledgment

Grant INCT-MM (FAPEMIG: CBB-APQ-00075-09/CNPq 573646/2008-2).

References

[1] I. Litvan, D. Aarsland, C. H. Adler et al., “MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI,” Movement Disorders, vol. 27, no. 3, pp. 349–356, 2011.
[2] R. C. Petersen, R. Doody, A. Kurz et al., “Current concepts in mild cognitive impairment,” Archives of Neurology, vol. 58, no. 12, pp. 1985–1992, 2001.
[3] E. Mamikonyan, P. J. Moberg, A. Siderowf et al., “Mild cognitive impairment is common in Parkinson’s disease patients with normal Mini-Mental State Examination (MMSE) scores,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. 226–231, 2009.
[4] A. I. Tröster, “A Précis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson’s disease and a proposal of preliminary research criteria,” Journal of the International Neuropsychological Society, vol. 17, no. 3, pp. 393–406, 2011.
[5] M. A. Hely, W. G. Reid, M. A. Adena, G. M. Halliday, and J. G. Morris, “The Sydney multicenter study of Parkinson’s disease and a proposal of preliminary research criteria,” Movement Disorders, vol. 23, pp. 837–844, 2008.
[6] C. C. Janvin, J. P. Larsen, D. Aarsland, and K. Hugdahl, “Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia,” Movement Disorders, vol. 21, no. 9, pp. 1343–1349, 2006.
[7] R. C. Petersen, R. O. Roberts, D. S. Knopman et al., “Mild cognitive impairment: ten years later,” Archives of Neurology, vol. 66, no. 12, pp. 1447–1455, 2009.
[8] J. L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D. A. Carusi, and J. Gornbein, “The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia,” Neurology, vol. 44, no. 12, pp. 2308–2314, 1994.
[9] S. M. Brucki, R. Nitrini, P. Caramelli, P. H. Bertolucci, and I. H. Okamoto, “Sugestões para o uso do Mini-Exame do Estado Mental no Brasil,” Arquivos de Neuro-Psiquiatria, vol. 61, pp. 777–781, 2003.
[10] R. I. Pfeffer, T. T. Kurosaki, and C. H. Harrah, “Measurement of functional activities in older adults in the community,” Journals of Gerontology, vol. 37, no. 3, pp. 323–329, 1982.
[11] P. H. F. Bertolucci, I. H. Okamoto, S. M. D. Brucki, M. O. Siviero, J. T. Neto, and L. R. Ramos, “Applicability of the CERAD neuropsychological battery to Brazilian elderly,” Arquivos de Neuro-Psiquiatria, vol. 59, no. 3, pp. 532–536, 2001.
[12] K. I. Shulman, “Clock-drawing: is it the ideal cognitive screening test?” International Journal of Geriatric Psychiatry, vol. 15, no. 6, pp. 548–561, 2000.
[13] T. A. Saltzhouse, “Localizing age-related individual differences in a hierarchical structure,” Intelligence, vol. 32, no. 6, pp. 541–561, 2004.
[14] C. S. Porto, H. C. Fichman, P. Caramelli, V. S. Bahia, and R. Nitrini, “Brazilian version of the Mattis dementia rating scale: diagnosis of mild dementia in alzheimer’s disease,” Arquivos de Neuro-Psiquiatria, vol. 61, no. 2, pp. 339–345, 2003.
[15] E. Matteu, N. Dupré, M. Langlois, P. Pronencher, and M. Simard, “Clinical validity of the Mattis dementia rating scale-2 in Parkinson disease with MCI and dementia,” Journal of Geriatric Psychiatry and Neurology, vol. 25, no. 2, pp. 100–106, 2012.
[16] J. J. de Paula, L. P. C. Melo, R. Nicolato et al., “Reliability and construct validity of the Rey-Auditory verbal learning test in Brazilian elders,” Revista de Psiquiatria Clinica, vol. 39, no. 1, pp. 19–23, 2012.
[17] R. T. Ávila, L. F. Malloy-Diniz, M. A. Bicalho, E. N. Moraes, and J. J. de Paula, “Avaliação das Praxias construtivas visuo-construtivas no idoso através da cópia de figuras e construção bidimensional: influência da idade, escolaridade e controle executivo,” Revista Médica de Minas Gerais, vol. 20, pp. 78–79.
[18] L. F. Malloy-Diniz, R. C. Bentes, P. M. Figueiredo et al., “Normalización de una batería de tests para evaluar las habilidades de compensación del lenguaje, fluidez verbal y denominacion en niños brasileños de 7 a 10 años: resultados preliminares,” Revista de Neurología, vol. 44, no. 5, pp. 275–280, 2007.
[19] J. J. de Paula, L. Bertola, R. Nicolato, E. N. de Moraes, and L. F. Malloy-Diniz, “Evaluating language comprehension in Alzheimer’s disease: the use of the Token Test,” Arquivos de Neuro-Psiquiatria, vol. 70, no. 6, pp. 435–440, 2012.
[20] M. A. Sédó and L. De Cristoforo, “All-language verbal tests free from linguistic barriers,” Revista Española de Neuropsicología, vol. 3, pp. 68–82, 2001.
[21] J. J. de Paula, D. S. Costa, E. N. Moraes, R. Nicolato, M. Sédó, and L. F. Malloy-Diniz, “Automatic and controlled attentional process in amnestic mild cognitive impairment: the use of a mini-verbal test,” Psychology, vol. 3, no. 5, pp. 379–383, 2012.
[22] O. Baiyewu, F. W. Unverzagt, K. A. Lane et al., “The Stick test: distinction between amnestic and non-amnestic mci,” Journal of the International Neuropsychological Society, vol. 37, no. 3, pp. 583–590, 2011.
[23] J. J. de Paula, L. Moreira, R. Nicolato et al., “The tower of London test: different scoring criteria for diagnosing Alzheimer’s disease and mild cognitive impairment,” Psychological Reports, vol. 110, no. 2, pp. 477–488, 2012.
[24] J. J. De Paula, C. G. Schloftfeldt, L. Moreira et al., “Psychometric properties of a brief neuropsychological protocol for use in geriatric populations,” Revista de Psiquiatria Clinica, vol. 37, no. 6, pp. 251–255, 2010.
[25] R. Cattelani, F. Dal Sasso, D. Corsini, and L. Posteraro, “The Modified Five-Point Test: normative data for a sample of Italian healthy adults aged 16–60,” Neurological Sciences, vol. 32, pp. 595–601, 2011.

[26] P. Barone, D. Aarsland, D. Burn, M. Emre, J. Kulisevsky, and D. Weintraub, “Cognitive impairment in nondemented Parkinson's disease,” Movement Disorders, vol. 26, no. 14, pp. 2483–2495, 2011.

[27] S. Martínez-Horta and J. Kulisevsky, “Is all cognitive impairment in Parkinson's disease “mild cognitive impairment”?” Journal of Neural Transmission, vol. 118, no. 8, pp. 1185–1190, 2011.

[28] J. Mintzer and A. Burns, “Anticholinergic side-effects of drugs in elderly people,” Journal of the Royal Society of Medicine, vol. 93, no. 9, pp. 457–462, 2000.

[29] L. F. Low, K. J. Anstey, and P. Sachdev, “Use of medications with anticholinergic properties and cognitive function in a young-old community sample,” International Journal of Geriatric Psychiatry, vol. 24, no. 6, pp. 578–584, 2009.

[30] M. P. Fortin, I. Rouch, V. Dauphinot et al., “Effects of anticholinergic drugs on verbal episodic memory function in the elderly: a retrospective, cross-sectional study,” Drugs and Aging, vol. 28, no. 3, pp. 195–204, 2011.

[31] J. L. Rudolph, M. J. Salow, M. C. Angelini, and R. E. McGlinchey, “The anticholinergic risk scale and anticholinergic adverse effects in older persons,” Archives of Internal Medicine, vol. 168, no. 5, pp. 508–513, 2008.

[32] M. S. Morris, P. F. Jacques, I. H. Rosenberg, and J. Selhub, “Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification,” American Journal of Clinical Nutrition, vol. 85, no. 1, pp. 193–200, 2007.

[33] A. D. Smith and H. Refsum, “Vitamin B-12 and cognition in the elderly,” American Journal of Clinical Nutrition, vol. 89, pp. 707–711, 2009.

[34] C. C. Tangney, N. T. Aggarwal, H. Li et al., “Vitamin B12, cognition, and brain MRI measures: a cross-sectional examination,” Neurology, vol. 77, no. 13, pp. 1276–1282, 2011.

[35] I. Blasko, M. Hinterberger, G. Kemmler et al., “Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort,” The Journal of Nutrition, Health, and Aging, vol. 16, no. 8, pp. 687–694, 2012.

[36] J. G. Z. Van Uffelen, M. J. M. Chinapaw, W. Van Mechelen, and M. Hopman-Rock, “Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial,” British Journal of Sports Medicine, vol. 42, no. 5, pp. 344–351, 2008.

[37] V. Elderkin-Thompson, A. Kumar, W. B. Bilker et al., “Neuropsychological deficits among patients with late-onset minor and major depression,” Archives of Clinical Neuropsychology, vol. 18, no. 5, pp. 529–549, 2003.

[38] T. Beblo, G. Simmon, and B. T. Baune, “Specifying the neuropsychology of affective disorders: clinical, demographic and neurobiological factors,” Neuropsychology Review, vol. 21, no. 4, pp. 337–359, 2011.

[39] C. E. Sexton, L. McDermott, U. G. Kalu et al., “Exploring the pattern and neural correlates of neuropsychological impairment’s in late-life depression,” Psychological Medicine, vol. 42, pp. 1195–1202, 2012.

[40] K. Jellinger, “Heterogenous mechanisms of mild cognitive impairment in Parkinson’s disease,” Journal of Neurotransmission, vol. 119, no. 3, pp. 381–382, 2012.